McGill researchers identify a centuries-old genetic mutation linked to pancreatic and breast cancer risk in Quebec’s French-Canadian population
Researchers at McGill University have identified an inherited genetic mutation that may help explain why some French-Canadians in Quebec face a significantly higher risk of pancreatic cancer. The discovery, published in the Journal of Medical Genetics, highlights how advances in genetic testing are uncovering previously undetectable cancer-related mutations and may eventually improve early screening strategies for high-risk families.
The findings are particularly important for Quebec families with a history of pancreatic or breast cancer, especially within French-Canadian communities whose ancestry traces back to a relatively small founder population from the 1600s.
What Is a “Jumping Gene”?
The mutation identified by researchers involves what scientists call a “jumping gene,” formally known as a transposable element. These are pieces of DNA capable of copying themselves and inserting into new locations within the genome.
In this case, the jumping gene inserted itself into the ATM gene — an important gene involved in repairing damaged DNA.
When the ATM gene becomes disrupted, the body’s ability to repair cellular DNA damage weakens. Over time, this can increase the likelihood of cancer development.
The researchers identified a specific mutation called: ATM c.7374_7375insAlu
which appears to have originated approximately 300 years ago, during the early settlement period of New France.
Understanding the Founder Effect in Quebec
The discovery also illustrates an important genetic concept known as the founder effect.
Because Quebec’s French-Canadian population descended from a relatively small number of early settlers, some rare genetic mutations became more common over generations. This phenomenon has already been observed with several inherited conditions in Quebec, and researchers now believe this newly identified ATM mutation is another example.
According to the McGill research team, this mutation was found in approximately:
- 2% of French-Canadian pancreatic cancer cases
- Compared to roughly 0.2% of unaffected individuals
This represents about a 10-fold increase in relative frequency among pancreatic cancer patients.
Researchers also observed the mutation more frequently in French-Canadian women with breast cancer, suggesting that it may contribute to increased breast cancer susceptibility as well.
Why This Discovery Matters
Pancreatic cancer remains one of the most serious and difficult-to-detect cancers. Symptoms often appear late, and many cases are diagnosed at advanced stages.
Identifying inherited risk factors may help clinicians:
- Detect high-risk individuals earlier
- Offer more personalized screening recommendations
- Improve family history assessments
- Guide referrals for genetic counselling
- Support preventive and surveillance strategies
Importantly, older generations of genetic testing often failed to detect these kinds of mutations. Traditional testing methods were designed primarily to identify small DNA sequence changes, not larger inserted genetic elements like jumping genes.
Newer sequencing technologies are now allowing scientists to uncover mutations that previously went unnoticed.
Should Patients Consider Genetic Counselling?
The study’s authors suggest that some individuals who underwent hereditary cancer testing years ago may benefit from re-evaluation, especially if they have:
- A strong family history of pancreatic cancer
- Multiple relatives with breast cancer
- French-Canadian ancestry
- Previous “negative” genetic testing performed 5–10 years ago
- Early-onset cancers within the family
Genetic counselling helps patients understand:
- Their inherited cancer risk
- Whether updated testing may be appropriate
- What screening or surveillance options exist
- The implications for relatives and family members
At Orleans Family Health Clinic, we encourage patients with significant family cancer histories to discuss these concerns with their primary care provider. Family physicians play a critical role in identifying patterns that may warrant referral to genetics specialists or hereditary cancer programs.
The Growing Role of Precision Medicine
This discovery reflects the broader evolution of precision medicine — tailoring healthcare based on a person’s genetic profile, medical history, and risk factors.
In the future, targeted “founder mutation” panels designed specifically for French-Canadian populations could potentially improve early identification of hereditary cancer risk in Quebec communities.
Researchers believe that testing for a small number of well-established founder mutations may eventually become a more efficient way to identify individuals who could benefit from enhanced cancer surveillance.
What Is the ATM Gene?
The ATM gene helps regulate cellular responses to DNA damage. When functioning normally, it acts as part of the body’s internal repair system.
Simplified conceptually: DNA Damage →ATM Activation→DNA Repair
When ATM function is impaired, damaged cells may continue dividing instead of being repaired or eliminated, increasing cancer risk over time.
Mutations in ATM have previously been associated with:
- Pancreatic cancer
- Breast cancer
- Prostate cancer
- Certain blood cancers
However, this newly identified French-Canadian founder mutation appears to represent a unique inherited risk factor within Quebec populations.
Key Takeaways for Patients
Patients should consider speaking with their healthcare provider if they:
- Have multiple family members with pancreatic or breast cancer
- Have French-Canadian ancestry and a strong cancer history
- Previously underwent older genetic testing
- Are concerned about inherited cancer risk
It is important to remember:
- Most pancreatic cancer cases are not caused by this mutation
- Having a mutation does not guarantee cancer will develop
- Genetic counselling should always accompany hereditary cancer testing
- Early risk identification may improve surveillance and preventive care planning
OFHC’s Approach to Preventive Family Medicine
At Orleans Family Health Clinic, preventive medicine and continuity of care remain central to our approach. Family physicians help patients navigate increasingly complex areas of medicine, including:
- Hereditary cancer risk assessment
- Family history analysis
- Preventive screening recommendations
- Specialist referrals
- Long-term chronic disease prevention
As genetic medicine advances, primary care providers will continue playing an essential role in helping patients interpret evolving evidence and make informed healthcare decisions.
Frequently Asked Questions
What is a “jumping gene”?
A jumping gene is a mobile piece of DNA capable of inserting itself into different parts of the genome, sometimes disrupting important genes.
What does the ATM gene do?
The ATM gene helps repair damaged DNA and maintain cellular stability.
Does this mutation only affect French-Canadians?
The mutation appears particularly enriched in Quebec’s French-Canadian population because of the founder effect, although ATM mutations can occur in many populations.
Should everyone get tested?
No. Genetic testing is usually recommended based on personal and family history, not for the general population without risk factors.
Can pancreatic cancer be inherited?
Yes. Some pancreatic cancers are associated with inherited genetic mutations, including BRCA1, BRCA2, PALB2, and ATM mutations.
Stay Connected with Orleans Family Health Clinic!
If you found this article helpful, don’t forget to like, share, and Follow to stay up to date on our latest health tips, updates, and wellness advice.
And follow us on social media
Disclaimer: The medical information on this site is provided as an information resource only and is not to be used or relied on for any diagnostic or treatment purposes. This information does not substitute for professional diagnosis and treatment. Please do not initiate, modify, or discontinue any treatment, medication, or supplement solely based on this information. Always seek the advice of your healthcare provider first. Full Disclaimer.
